Title Image

Material Information- Announces Handa Pharmaceuticals, Inc., and on behalf of the subsidiaries, regarding the 505(b)(2) new formulation drug HND-039 patent infringement lawsuit

Material Information- Announces Handa Pharmaceuticals, Inc., and on behalf of the subsidiaries, regarding the 505(b)(2) new formulation drug HND-039 patent infringement lawsuit

1.Parties to the legal matter:
Plaintiff:Exelixis, Inc
Defendant:Handa Pharmaceuticals, Inc., Handa Pharma, Inc. and Handa Oncology, LLC
2.Name of the court or punishing agency of the legal matter:
United States District Court for DELAWARE
3.Reference/Case number of relevant documents of the legal matter:
NO. 1:26-cv-01412-UNA
4.Date of occurrence of the event:2026/11/04
5.Details of occurrence (including the matter under dispute):
On November 03, 2026 (GMT-5), Handa Pharmaceuticals, Inc., the subsidiaries HandaPharma, Inc. and Handa Oncology, LLC received a patent infringement notice from Exelixis, Inc.
6.Handling procedure:
As this kind of litigation is a common aspect of competition within the pharmaceutical industry, the Company has already engaged attorneys to respond to the legal dispute. The Company will actively defend its rights to HND-039 in accordance with U.S. law and practice and seek to resolve the dispute as soon as possible.
7.Impact on the Company’s finance and business and projected amount:
Attorneys will handle subsequent matters according to legal procedures. As of now, there is no material impact on the Company’s operations or financial condition.
8.Countermeasures and improvement status:
The Company will actively cooperate with attorneys in all matters related to the patent litigation.
9.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 2 of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of the securities on public companies.):
(1)In the US pharmaceutical market, companies may assert their patent rights by initiate patent infringement proceedings. Such patent disputes are a common feature of competition in the US pharmaceutical industry. The Company has always valued the protection of intellectual property and is well prepared. The Company will continue to execute its previously planned product launch and business development strategies as scheduled.
(2)Drug development involves long timelines, high costs, and requires regulatory review. The approval timeline is uncertain and success is not guaranteed, which may pose investment risks. Investors should exercise caution and make prudent judgments.